Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicocodine SCHEMBL159020 | 1.00 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicocodine SCHEMBL29531263 | 1.00 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL26237 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL680036 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29408441 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29349768 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL1649977 | 0.93 | OPRD1 (0.68) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL395672 | 0.93 | OPRD1 (0.68) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8418756 | 0.91 | OPRM1 (0.76) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769499 | 0.87 | OPRM1 (0.75) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20220211616-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2022-07-07 | — | — | US | claimed |
| EP-3682872-A1 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| US-20070224129-A1 | Anti-misuse microparticulate oral pharmaceutical form | FLAMEL TECHNOLOGIES, INC. (FR) | 2007-09-27 | — | — | US | claimed |
| US-20070202049-A1 | Oral dosage form comprising an antimisuse system | FLAMEL TECHNOLOGIES, INC. (FR) | 2007-08-30 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007054378-A1 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM | FLAMEL TECHNOLOGIES (FR) | 2007-05-18 | — | — | WO | claimed |
| WO-2006134018-A2 | ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM | FLAMEL TECHNOLOGIES (FR) | 2006-12-21 | — | — | WO | claimed |
| WO-2006133733-A1 | ORAL DOSAGE FORM COMPRISING AN ANTIMISUSE SYSTEM | FLAMEL TECHNOLOGIES (FR) | 2006-12-21 | — | — | WO | claimed |
| CN-1872063-A | Microspheres or composition in use for long acting injection of Nalmefene or its salt, and preparation method | TOXICS & MEDICINES INST A M M (CN) | 2006-12-06 | — | — | CN | claimed |
| WO-2006089843-A2 | ANTI-MISUSE MICROPARTICULATE ORAL DRUG FORM | FLAMEL TECHNOLOGIES (FR) | 2006-08-31 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |